Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
NCT02815332 · View on ClinicalTrials.gov ↗
Study Summary
This is a 12-week, multi-center, double-blind, randomized, three-arm, vehicle-controlled study. Subjects will be randomized (1:1:1) to 1% or 2 % BPX-01 gel, or vehicle. Subjects will apply 1g of the gel as a thin film to the entire face at least 30 minutes before bedtime each night for 12 weeks. Lesion counts, IGA, and Patient-Reported Outcomes (PGI-S and PGI-I) will be performed to assess efficacy. Blood draws will be collected at baseline (Day 0), and at Weeks 4 and 12 to evaluate the level of minocycline in plasma. Safety will be assessed with the vital signs, brief physical examination, clinical laboratory tests, cutaneous tolerance score, incidence of minocycline-induced skin hyperpigmentation, incidence of visual disturbances and/or headaches suggestive of pseudotumor cerebri, and collection of adverse events.
Conditions Studied
Interventions
- DRUG BPX-01 1% Minocycline Topical Gel
- DRUG BPX-01 2% Minocycline Topical Gel
- DRUG BPX-01 Vehicle Topical Gel
Study Locations (15)
Texas
- — Pflugerville
- — Plano
- — San Antonio
Florida
- — Coral Gables
- — Lake Mary
Tennessee
- — Murfreesboro
- — Nashville
California
- — Santa Monica
Georgia
- — Newnan
Kentucky
- — Louisville
Nevada
- — Las Vegas
New Jersey
- — Montclair
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-03-24 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02815332
The ClinicalTrials.gov registry entry for NCT02815332 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioPharmX, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 3 interventions — of which BPX-01 1% Minocycline Topical Gel is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02815332 reports 15 study locations spanning 11 distinct geographic areas — top geographies include Texas, Florida, Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02815332 about?
NCT02815332 is a clinical study titled "BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris". This is a 12-week, multi-center, double-blind, randomized, three-arm, vehicle-controlled study. Subjects will be randomized (1:1:1) to 1% or 2 % BPX-01 gel, or vehicle. Subjects will apply 1g of the gel as a thin film to the entire face at least 30 minutes before bedtime each night for 12 weeks. Le...
What is the current status of trial NCT02815332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2016-08. Estimated completion is 2017-03-24.
What conditions does trial NCT02815332 study?
This clinical trial studies the following conditions: Acne Vulgaris. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02815332?
The interventions under investigation include: BPX-01 1% Minocycline Topical Gel (DRUG), BPX-01 2% Minocycline Topical Gel (DRUG), BPX-01 Vehicle Topical Gel (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02815332?
This trial is sponsored by BioPharmX, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02815332 being conducted?
This trial has 15 study locations across California, Florida, Georgia, Kentucky, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.